Scientists will soon begin testing a new drug for its potential to treat triple-negative breast cancer, The Telegraph reported.
Researchers at the Dana-Farber Cancer Institute in Boston recently identified a pool of 15 genes associated with accelerating the growth of this aggressive disease.
The discovery will now allow scientists to begin clinical trials on a drug that will hopefully work in slowing or stopping the development of triple-negative breast cancer tumors.
Unlike other forms of the disease, triple-negative breast cancer does not respond to drugs typically used to treat this condition.
Although the clinical trials are still in an early stage, researchers are looking forward to the possibility of achieving one of the first specific therapies for triple-negative breast cancers, a disease which currently afflicts more than 40,000 women a year.